Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Camostat mesilate - Daewoong Pharmaceutical

Next Previous
Drug Profile

Camostat mesilate - Daewoong Pharmaceutical

Alternative Names: Camostat Mesylate - Daewoong Pharmaceutical; DWJ-1248; Foistar

Latest Information Update: 13 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Anti-inflammatories; Antineoplastics; Antiulcers; Antivirals; Benzene derivatives; Guanidines; Inorganic sulfur compounds; Small molecules
  • Mechanism of Action Peptide hydrolase inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III COVID 2019 infections

Most Recent Events

  • 27 Sep 2023 Daewoong Pharmaceutical terminates a phase III trial in COVID-2019 infections (Combination therapy, In adults, In the elderly) in South Korea (PO) (NCT04713176)
  • 04 Dec 2022 Daewoong Pharmaceutical terminates a phase III trial in COVID-2019 infections (Prevention, In adults, In the elderly) in South Korea (PO, Tablet) (NCT04721535)
  • 18 Mar 2022 Daewoong Pharmaceutical terminates a phase II/ III trial in COVID-2019 infection in South Korea (PO) due to changes in drug development plans (NCT04521296)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top